SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3362)4/6/2001 2:42:55 PM
From: Michael Young  Read Replies (2) | Respond to of 52153
 
A biotech is cheap in a bear market if it has a drug or two near approval that can justify the market cap.

MLNM is an excellent company. But I don't really see the stock keeping a $6 billion market cap in this environment.

HGSI probably even more vulnerable however.

Both those stocks are still held by too many "weak hands."

MIKE



To: scaram(o)uche who wrote (3362)4/11/2001 7:28:47 PM
From: sammaster  Read Replies (1) | Respond to of 52153
 
this stock for the long haul is cheap with its potential to be a big pharma like amgen and others...
great pipeline..
lots of cash...
great partnerships...

that being said im afraid of jumping in because of the probable recession which will initially cause liquidation of funds although biotechs will be among the first to rebound because of their defensive nature


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News